PDE5 inhibitors: targeting erectile dysfunction in diabetics
PDE5 inhibitors: targeting erectile dysfunction in diabetics
复制标题
DOI：
10.1016/j.coph.2011.08.004
复制
发表时间：
2011-12-01
影响因子：
4
通讯作者：
Corbin, Jackie D.
中科院分区：
文献类型：
--
作者：
Francis, Sharron H.;Corbin, Jackie D.
勃起功能障碍（艾德）与心血管疾病（CVD）密切相关，尤其是在糖尿病患者中。艾德与整体血管系统的有害变化相关，并被认为是不良心血管事件风险较高的指标。内皮功能障碍、血管平滑肌变化和纤维化增加被认为是艾德和CVD的主要因素。与非糖尿病患者相比，糖尿病患者的艾德对磷酸二酯酶-5（PDE 5）抑制剂（万艾可、希爱力、艾力达、Zydena）的急性治疗更难治，但最近的研究表明，这些药物的长期给药可改善内皮功能，保护血管平滑肌并减少纤维化变化。在糖尿病前期和糖尿病男性中使用PDE 5抑制剂可以保护心血管健康，包括阴茎组织中的血管功能。
Erectile dysfunction (ED) is strongly linked to cardiovascular disease (CVD), especially in diabetics. ED is associated with deleterious changes in the overall vasculature and is recognized as an indicator of higher risk for adverse cardiovascular events. Endothelial dysfunction, vascular smooth muscle changes and increased fibrosis are indicated as major players in both ED and CVD. ED in diabetics is more refractory to acute treatment with phosphodiesterase-5 (PDE5) inhibitors (Viagra, Cialis, Levitra, Zydena) than in non-diabetics, but recent studies indicate that chronic administration of these drugs improves endothelial function, preserves vascular smooth muscle and decreases fibrotic changes. Use of PDE5 inhibitors in pre-diabetic and diabetic men may protect cardiovascular health, including vascular function in penile tissues.